

**SB239 INTRODUCED**



1 KYD6AA-1  
2 By Senator Stutts  
3 RFD: Healthcare  
4 First Read: 25-Apr-23  
5  
6 2023 Regular Session



1  
2  
3

4     SYNOPSIS:

5                     The Medication Assisted Treatment of Opioid Use  
6     Act of 2019 ("MAT Act"), requires the Alabama Board of  
7     Medical Examiners to adopt rules governing the  
8     prescribing and use of medications containing  
9     buprenorphine to treat opioid addiction in the  
10    nonresidential setting. The rules authorized by The MAT  
11    Act relate to dosage, screening, therapy, and  
12    record-keeping related to treatment with buprenorphine.  
13    A standard working group with members who specialize in  
14    addiction is also provided to assist in adoption of the  
15    rules.

16                     Since enactment, changes in federal law and  
17    policy governing medication-assisted treatment of  
18    opioid addiction have created conflicts with the  
19    provisions of the MAT Act.

20                     This bill would repeal the MAT Act.

21  
22

23                     A BILL

24                     TO BE ENTITLED  
25                     AN ACT

26  
27                     Relating to Opioid Addiction Treatment; to repeal the  
28    Medication Assisted Treatment of Opioid Use Act of 2019,

**SB239 INTRODUCED**



29 codified as Sections 20-2-300 through 20-2-302, Code of  
30 Alabama 1975, that provide for adoption of rules governing use  
31 of buprenorphine in the treatment of opioid addiction and a  
32 standing working group to assist in drafting the rules.

33 BE IT ENACTED BY THE LEGISLATURE OF ALABAMA:

34 Section 1. Sections 20-2-300 through 20-2-302, Code of  
35 Alabama 1975, known as The Medication Assisted Treatment of  
36 Opioid Use Act of 2019 and providing for the development and  
37 adoption of rules by the Alabama Board of Medical Examiners,  
38 with the consultation and assistance of a standing working  
39 group, for the treatment of opioid-addicted individuals with  
40 buprenorphine in a nonresidential setting, are repealed.

41 Section 2. This act shall become effective on the first  
42 day of the third month following its passage and approval by  
43 the Governor, or its otherwise becoming law.